the effects of BCG IV were initially done in the 1970s. practically speaking that would be a pretty tough route to sell. the excitement is over having a model of protection, understanding how it works and developing a vaccine out of that knowledge.

thanks Oded; that is reassuring! I think that could be clarified in the FAQ section "Deleting a manuscript immediately ends qed’s licence to use it..Any model parameters already learned or anonymized stats remain because they cannot technically be rolled back, but they contain no identifiable text."

this sounds cool. question: if someone uploads and later deletes a manuscript but it has already been used for training how do you know what the model has been trained on? is there any validation of the submission (what happens if someone writes a terrible paper or provides false data?)

sounds interesting and i look forward to reading it! from the abstract it reminds me of an old paper P. Bousso's group had on T cells; I always thought the finding was fascinating: journals.plos.org/plosone/arti...

dinner at the opera house in Copenhagen at the near end of a fantastic meeting, Novo Nordisk Foundation Science Cluster: Harnessing airway immunity for next-gen vaccines

truly - so glad to be a part of this community!!!